Literature DB >> 4041682

Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an insurmountable histamine H2-receptor blocking drug.

R T Brittain, D Jack, J J Reeves, R Stables.   

Abstract

The very late occurrence of gastric carcinoids in a life-span carcinogenicity study with loxtidine in the rat might have resulted from continuous achlorhydria induced by this long-acting unsurmountable histamine H2-antagonist. The nature of the anti-secretory activity of loxtidine was compared with that of ranitidine on histamine-induced acid secretion in the perfused stomach preparation of the rat and in the rat isolated gastric mucosa preparation. Ranitidine and loxtidine had qualitatively different inhibitory effects on acid secretion, ranitidine being a competitive antagonist of histamine even at high concentrations, whereas the effect of loxtidine on both preparations was unsurmountable at relatively low concentrations. These results support the hypothesis that the late formation of gastric carcinoids in rats receiving loxtidine is a consequence of persistent achlorhydria caused by unsurmountable blockade of parietal cell H2-receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4041682      PMCID: PMC1916673          DOI: 10.1111/j.1476-5381.1985.tb11083.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  3 in total

1.  Continuous recording of acid gastric secretion in the rat.

Authors:  M N GHOSH; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1958-03

2.  Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine.

Authors:  M J Daly; J M Humphray; R Stables
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

3.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03
  3 in total
  19 in total

1.  Dimethyl sulfoxide inhibits histamine release induced by various chemicals.

Authors:  L Candussio; F B Klugmann; G Decorti; S Bevilacqua; L Baldini
Journal:  Agents Actions       Date:  1987-02

2.  1976 and all that!--20 years of antisecretory therapy.

Authors:  A Garner; H Fadlallah; M E Parsons
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 3.  Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease.

Authors:  J G Penston; K G Wormsley
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 4.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 5.  Achlorhydria: hypergastrinaemia: carcinoids--a flawed hypothesis?

Authors:  J Penston; K G Wormsley
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

Review 6.  H2-receptor antagonists and gastric cancer.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun

7.  Inhibition of human gastric secretion by ICI 162,846--a new histamine H2-receptor antagonist.

Authors:  J A Wilson; D A Johnston; J Penston; K G Wormsley
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

8.  Role of prostaglandins and histamine in hyperemic response to superficial and deep gastric mucosal injury and H+ back-diffusion in cats.

Authors:  H Gislason; H Sørbye; F Abdi-Dezfuli; H L Waldum; K Svanes
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

10.  Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome.

Authors:  G E Feurle
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.